1. Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: a systematic review and meta-analysis. Cancer Epidemiol 2022; 79: 102203.
2.
Ruggiero A, Trombatore G, Triarico S, et al. Platinum compounds in children with cancer. Anticancer Drugs 2013; 24: 1007-1019.
3.
Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 2009; 219: 177-186.
4.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
5.
Matchar DB. Chapter 1: Introduction to the methods guide for medical test reviews. J Gen Intern Med 2012; 27: 4-10.
6.
Wells G, Shea B, O’Connell D, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
7.
Clemens E, Brooks B, de Vries ACH, van Grotel M, van den Heuvel-Eibrink MM, Carleton B. A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. PLoS One 2019; 14: e0210646.
8.
Al-Khatib T, Cohen N, Carret AS, Daniel S. Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol 2010; 74: 913-919.
9.
Moke DJ, Luo C, Millstein J, et al. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. Lancet Child Adolesc Health 2021; 5: 274-283.
10.
Weiss A, Sommer G, Kasteler R, et al. Long-term auditory complications after childhood cancer: a report from the Swiss childhood cancer survivor study. Pediatr Blood Cancer 2017; 64: 364-373.
11.
Kersten MJ, Driessen J, Zijlstra JM, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica 2020; 106: 1129-1137.
12.
Meyer AK, Young NM. Auditory late effects of chemotherapy. In: Late effects of treatment for brain tumors. Goldman S, Turner CD (eds.). springer, berlin 2009, 195-213.
13.
Hellberg V, Wallin I, Eriksson S, et al. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Canser Inst 2009; 101: 37-47.
14.
Hodge SE, Lopez IA, Ishiyama G, Ishiyama A. Cisplatin ototoxicity histopathology. Laryngoscope Investig Otolaryngol 2021; 6: 852-856.
15.
Einarsson EJ, Petersen H, Wiebe T, Fransson PA, Måns M, Moëll C. Severe difficulties with word recognition in noise after platinum chemotherapy in childhood, and improvements with open-fitting hearing-aids. Int J Audiol 2011; 50: 642-651.
16.
Brooks B, Knight K. Ototoxicity monitoring in children treated with platinum chemotherapy. Int J Audiol 2018; 57: S62-S68.
17.
Punnett A, Bliss B, Dupuis LL, Abdolell M, Doyle J, Sung L. Ototoxicity following pediatric hematopoietic stem cell transplantation: A prospective cohort study. Pediatr Blood Cancer 2004; 42: 598-603.
18.
Meijer AJM, Clemens E, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM. Tinnitus during and after childhood cancer: A systematic review. Crit Rev Oncol Hematol 2019; 135: 1-7.
19.
MacAruso N, Campbell K, Cost C, Sopfe J. ASPHO Conference Paper and Poster Index. Pediatr Blood Cancer 2020; 67.
20.
Skarzyński H, Gos E, Raj-Koziak D, Skarzyński PH. Skarzynski Tinnitus scale: validation of a brief and robust tool for assessing tinnitus in a clinical population. Eur J Med Res 2018; 23: 1-14.
21.
Einarsson EJ, Oskarsson T, Haraldsson A, et al. Hearing impairment after platinum-based chemotherapy in childhood. Pediatr Blood Cancer 2011; 56: 631-637.
22.
A predictive model for aggressive non-Hodgkin’s lymphoma. N En J Med 1993; 329: 987-994.
23.
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130: 1800-1808.
24.
Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26: 649-655.
25.
Meijer AJM, van den Heuvel-Eibrink MM, Brooks B, et al. Recommendations for age-appropriate testing, timing, and frequency of audiologic monitoring during childhood cancer treatment. JAMA Oncol 2021; 7: 1550.
26.
Clemens E, van den Heuvel-Eibrink MM, Mulder RL, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol 2019; 20: e29-e41.
27.
Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007; 25: 1190-1195.
28.
Abdulaziz-Opiela G, Sobieraj A, Płotka A, Więckowska B, Gil L, Derwich K. Comparison of diagnostic and treatment processes among pediatric and adolescents and young adults’ populations suffering from acute lymphoblastic leukemia and lymphomas. Front Oncol 2023; 13.
29.
Gertson K, Hayashi SS, Trinkaus K, Wan F, Hayashi RJ. Prevalence of ototoxicity following hematopoietic stem cell transplantation in pediatric patients. Biol Blood Marrow Transplant 2020; 26: 107-113.
30.
Janowiak-Majeranowska A, Osowski J, Mikaszewski B, Majeranowski A. Secondary oral cancer after systemic treatment of hematological malignancies and oral GVHD: a systematic review. Cancers (Basel) 2022; 14: 2175.
31.
Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a New International Society of Pediatric Oncology Boston Ototoxicity scale. J Clin Oncol 2012; 30: 2408-2417.
32.
Waissbluth S. Clinical trials evaluating transtympanic otoprotectants for cisplatin-induced ototoxicity: what do we know so far? Eur Arch Otorhinolaryngol 2020; 277: 2413-2422.
33.
Freyer DR, Sung L, Reaman GH. Prevention of hearing loss in children receiving cisplatin chemotherapy. J Clin Oncol 2009; 27: 317-318.
34.
Laurell G. Pharmacological intervention in the field of ototoxicity. HNO 2019; 67: 434-439.
